Pharmaceutical companies can spend 10 to 15 years and more than $2.3 billion to bring new drugs to market. Despite these significant investments in drug development, 90% of clinical trials fail.
For a greater chance of success, pharmaceutical companies must emphasize clinical trial validity to ensure that the outcomes are relevant and applicable to patients in real-world clinical settings and that the results can withstand increased scrutiny from the Food and Drug Administration (FDA).
“By saying your clinical trial is valid, you’re saying that the results are meaningful and interpretable,” explains Paul Williams, Psy.D., senior pharma account manager for Pearson Assessments. “To make this claim, every aspect of the study must be held to very high standards.”
